Relationship: 1516



Oxidative Stress leads to Liver Cancer

Upstream event


Oxidative Stress

Downstream event


Liver Cancer

Key Event Relationship Overview


AOPs Referencing Relationship


AOP Name Directness Weight of Evidence Quantitative Understanding
Chronic Cyp2E1 Activation Leading to Liver Cancer indirectly leads to Moderate Not Specified

Taxonomic Applicability


Sex Applicability


Life Stage Applicability


How Does This Key Event Relationship Work


There are a variety of ways in which oxidative stress can lead indirectly to cancer. The main routes involve: (a) reactive oxygen species (ROS) that cause cytotoxicity, followed by regenerative proliferation leading to cancer; (b) ROS-induced DNA damage leading to mutations in cancer-driver genes and subsequently cancer; and (c) oncogenic effects of the up-regulation of NRF2. The focus of this iKER is on (b) and (c), as the details of (a) are mapped out elsewhere.

The types of genotoxic oxidative DNA damage that may occur following exposure to ROS have been extensively reviewed previously (Dizdaroglu 2012, Dizdaroglu 2015). Briefly, ROS can react with nitrogenous bases to produce various adducts that may be converted into a mutation following DNA replication. Further, ROS can damage the sugar phosphate backbone of DNA leading to abasic sites and strand breaks. If DNA damage leads to mutations that increases the expression of oncogenes or decreases the expression of tumour suppressor or DNA damage repair genes, they will transform normal cells into malignant cells. It is generally thought that liver cancer results from an accumulation of mutations in key cancer-driving genes such as TP53 and CTNNB1 (Fujimoto, et al. 2016, Shibata and Aburatani 2014a) (http://atlasgeneticsoncology.org/Tumors/HepatoCarcinID5039.html). 

In addition to DNA damage, at the molecular level, chronic activation of the Nrf2 oxidative stress response has been linked to promoting malignant transformation in pre-cancerous cells. Persistent Nrf2 activation results in the long-term up-regulation of antioxidant genes (which protect cancer cells that are known to have elevated ROS) and phase II metabolism genes (which facilitate the rapid metabolism of chemotherapeutics) (Kansanen, et al. 2013) providing a favourable environment for growth of pre-cancerous cells. The connection between chronically activated Nrf2 and cancer has been extensively studied and reviewed, most recently by Furfaro et al. (2016) and Karin and Dhar (2016). Further, Nrf2 control over cellular proliferation and differentiation has also been studied; reviewed most recently by Murakami and Motohashi  (2015). 


Weight of Evidence


Biological Plausibility



ROS-dependent DNA damage causing harmful mutations is known to occur. However, the specific mechanism and the quantitative relationships by which these mutations promote malignant transformation are incompletely understood.

Increase in NRF2 expression is associated with occurrence and recurrence of hepatocellular carcinoma; however, the mechanism is incompletely understood.

Empirical Support for Linkage



Carcinogens that cause cancer by ‘cytotoxicity and regenerative proliferation’ are generally accepted to be indirectly genotoxic. The most plausible source of indirect genotoxicity for these compounds are ROS. The following examples involve chemicals that are known rodent and/or human carcinogens. These data demonstrate that exposure leads to oxidative DNA damage, which may cause mutations required for malignant transformation. Overall, a variety of lines of evidence support the relationship between oxidative stress with the development and progression of hepatocellular carcinoma in humans. For example, reduced superoxide dismutase 2 (an antioxidant gene) mRNA and protein expression is correlated with mortality of hepatitis B virus-associated hepatocellular carcinoma patients in a mutant p53-dependent manner (Wang, et al. 2016b). This decrease in expression is accompanied by decreased copy number of the gene in tumours, supporting a genetic basis for the molecular phenotype. Plasma protein carbonyl content (biomarker of oxidative stress) is significantly higher, whereas plasma TAC (biomarker of antioxidant capacity) is significantly lower in hepatitis B virus-associated HCC patients with than healthy controls (Poungpairoj, et al. 2015). Exposure of human HepG2 cells to 2-Amino-9H-pyrido[2,3-b]indole (AαC) leads to increased levels of ROS and 8-OHdG, and decreased GSH/GSSG ratio  (Zhang, et al. 2015). Subsequent investigations showed that the concentration of 8-OHdG was positively related to DNA damage measured by the comet assay, indicating a role for genotoxicity in cancer for this compound.

Furan is not directly genotoxic; any observed genotoxicity following furan exposure is thought to be due to ROS-induced DNA damage. Oxidative DNA adducts (8-oxo-dG) have been observed following a three month exposure to a high dose of furan (30 mkd) (Hickling, et al. 2010). These 8-oxo-dG adducts were observed together with high levels of Cyp2E1 expression (the potential source of the ROS), apoptosis, necrosis, and proliferation in rat livers. Male mice exposed to a carcinogenic dose of furan (8 mkd) presented with increased levels of 8-OHdG DNA adducts, which could be prevented through co-treatment with apigenin (Wang, et al. 2014); global gene expression analysis of mice exposed at 8 mkd have also been shown to have increased expression of the Nrf2 oxidative stress response pathway (Jackson, et al. 2014). Rats exposed to furan (0, 2, 4, 8, 12 and 16 mkd) presented with dose-dependent increases in oxidized nitrogenous bases and double strand breaks, which were repaired in a time-dependent manner and in conjunction with an increase in expression of DNA repair genes (Ding, et al. 2012). Increases in DNA oxidative lesions, and supporting evidence from measures of gene expression changes, occur at doses that are aligned with those causing liver cancer in the same rodent models (furan-dependent liver cancer occurs at 2 mkd and up in rats and 4 mkd in mice) (Moser, et al. 2009, NTP 1993). Further, they occur at earlier time points than the corresponding carcinogenesis.

By-products of lipid peroxidation (MDA, 4-HNE) react with DNA to form etheno-DNA adducts (particularly, εdA and εdC), these adducts have been observed in vitro and in human patients, and are correlated with hepatocarcinogenesis (Linhart, et al. 2014, Wang, et al. 2009, Winczura, et al. 2012). Male Wistar rats exposed for one month to 35% ethanol had abasic sites, Ogg1-sensitive sites, and increased expression of BER genes in liver DNA; this ROS-dependent DNA damage occurs at earlier time points than the corresponding carcinogenesis.

Chloroform and carbon tetrachloride cause GSH depletion in human HepG2 cells, which leads to ROS and subsequent DNA strand breaks, 8-oxodeoxyguanosine (8-oxodG) DNA adducts, malondialde hydedeoxyguanosine (M1dG) DNA adducts, and lipid peroxidation (Beddowes, et al. 2003). Using cultured hepatocytes from female Wistar rats, the same study reported dose-dependent increases in glutathione depletion and lipid peroxidation (LPO) following treatment with chloroform (0, 0.8, 2.4, 4, 8, 20 mM; results reported 2 hours following exposure) or carbon tetrachloride (0, 0.25, 1, 4 mM; results reported 2 hours following exposure).  Further, the chloroform-exposed cells had dose-dependent increases in M1dG adducts and DNA strand breakage; and the carbon tetrachloride-exposed cells had dose-dependent increases in M1dG adducts, DNA strand breaks, and 8-oxodG adducts. Dose concordance of chloroform was demonstrated and significant changes occurred at the following doses: LPO (4, 8, 20 mM), decreased cell viability (20 mM), GSH depletion (20 mM), COMET (8, 20 mM), M1dG levels (4, 8, 20 mM). Further, GSH depletion was measured over a 24 hour period and was significantly decreased at 4, 8 and 24 hours following exposure to chloroform. Similar results were reported for carbon tetrachloride; however the data was not shown. Significant changes were reported for: LPO (4mM mM), decreased cell viability (4 mM), COMET (1 and 4 mM), M1dG levels (1 and 4 mM), and 8-oxo-dG (4 mM) following exposure to carbon tetrachloride (Beddowes, et al. 2003). Carbon tetrachloride-dependent oxidative adducts have also been reported elsewhere (Takahashi, et al. 1998, Wacker, et al. 2001). These studies demonstrate that oxidative damage to DNA occurs before liver cancer.

The transcriptional actions of chronic Nrf2 activation provide a molecular environment that promotes malignant transformation (Furfaro, et al. 2016, Jaramillo and Zhang 2013, Xiang, et al. 2014). Most recently, this relationship was outlined in an award-winning article that was published in the journal Carcinogenesis: The 2016 Carcinogenesis Award Winners “Liver carcinogenesis: from naughty chemicals to soothing fat and the surprising role of NRF2” (Karin and Dhar 2016). Following the analysis of the empirical data, the authors conclude that NRF2 is required for hepatocellular carcinoma precursor cells (HcPC) to progress to become hepatocellular carcinoma cells; in fact, without NRF2 excess ROS accumulate and kill the HcPC cells. Importantly, sequencing of human hepatocellular carcinoma patients has demonstrated NRF2 activation (Schulze, et al. 2015, Shibata and Aburatani 2014b, Totoki, et al. 2014). Following furan exposure at carcinogenic doses (4, 8 mkd), the NRF2 oxidative stress pathway was the most highly implicated molecular pathway following microarray analysis of gene expression in mice exposed for three weeks (Jackson, et al. 2014), which demonstrates that the NRF2 oxidative stress pathway becomes active after chemical exposure and before the development of hepatocellular carcinoma. Further, the level of induction of the NRF2 pathway (i.e., the number of implicated genes) increased with dose, which demonstrates dose dependence of the response, which is concordant with the dose-dependent increases in hepatocellular adenoma and carcinoma. While the mechanistic details remain under investigation, there is clearly an important interplay between the two branches of this response (i.e., ROS-dependent mutations and the NRF2 oxidative stress response).

Uncertainties or Inconsistencies


Not all agents that cause ROS in the liver cause liver cancer. Thus, there are additional modulating factors that must be considered when determining whether a ROS-producing chemical will cause liver cancer.

Quantitative Understanding of the Linkage


Unable to determine.

Evidence Supporting Taxonomic Applicability




Beddowes, E.J., Faux, S.P., Chipman, J.K., 2003. Chloroform, carbon tetrachloride and glutathione depletion induce secondary genotoxicity in liver cells via oxidative stress. Toxicology 187, 101-115.

Ding, W., Petibone, D.M., Latendresse, J.R., Pearce, M.G., Muskhelishvili, L., White, G.A., Chang, C.-., Mittelstaedt, R.A., Shaddock, J.G., McDaniel, L.P., Doerge, D.R., Morris, S.M., Bishop, M.E., Manjanatha, M.G., Aidoo, A., Heflich, R.H., 2012. In vivo genotoxicity of furan in F344 rats at cancer bioassay doses. Toxicol. Appl. Pharmacol. 261, 164-171.

Dizdaroglu, M., 2015. Oxidatively induced DNA damage and its repair in cancer. Mutat. Res. Rev. Mutat. Res. 763, 212-245.

Dizdaroglu, M., 2012. Oxidatively induced DNA damage: mechanisms, repair and disease. Cancer Lett. 327, 26-47.

Fujimoto, A., Furuta, M., Totoki, Y., Tsunoda, T., Kato, M., Shiraishi, Y., Tanaka, H., Taniguchi, H., Kawakami, Y., Ueno, M., Gotoh, K., Ariizumi, S., Wardell, C.P., Hayami, S., Nakamura, T., Aikata, H., Arihiro, K., Boroevich, K.A., Abe, T., Nakano, K., Maejima, K., Sasaki-Oku, A., Ohsawa, A., Shibuya, T., Nakamura, H., Hama, N., Hosoda, F., Arai, Y., Ohashi, S., Urushidate, T., Nagae, G., Yamamoto, S., Ueda, H., Tatsuno, K., Ojima, H., Hiraoka, N., Okusaka, T., Kubo, M., Marubashi, S., Yamada, T., Hirano, S., Yamamoto, M., Ohdan, H., Shimada, K., Ishikawa, O., Yamaue, H., Chayama, K., Miyano, S., Aburatani, H., Shibata, T., Nakagawa, H., 2016. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat. Genet. 48, 500-509.

Furfaro, A.L., Traverso, N., Domenicotti, C., Piras, S., Moretta, L., Marinari, U.M., Pronzato, M.A., Nitti, M., 2016. The Nrf2/HO-1 Axis in Cancer Cell Growth and Chemoresistance. Oxid Med. Cell. Longev 2016, 1958174.

Hickling, K.C., Hitchcock, J.M., Oreffo, V., Mally, A., Hammond, T.G., Evans, J.G., Chipman, J.K., 2010. Evidence of oxidative stress and associated DNA damage, increased proliferative drive, and altered gene expression in rat liver produced by the cholangiocarcinogenic agent Furan. Toxicol. Pathol. 38, 230-243.

Jackson, A.F., Williams, A., Recio, L., Waters, M.D., Lambert, I.B., Yauk, C.L., 2014. Case study on the utility of hepatic global gene expression profiling in the risk assessment of the carcinogen furan. Toxicol. Appl. Pharmacol. 274, 63-77.

Jaramillo, M.C., Zhang, D.D., 2013. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 27, 2179-2191.

Kansanen, E., Kuosmanen, S.M., Leinonen, H., Levonen, A.L., 2013. The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. Redox Biol. 1, 45-49.

Karin, M., Dhar, D., 2016. Liver carcinogenesis: from naughty chemicals to soothing fat and the surprising role of NRF2. Carcinogenesis 37, 541-546.

Linhart, K., Bartsch, H., Seitz, H.K., 2014. The role of reactive oxygen species (ROS) and cytochrome P-450 2E1 in the generation of carcinogenic etheno-DNA adducts. Redox Biol. 3, 56-62.

Moser, G.J., Foley, J., Burnett, M., Goldsworthy, T.L., Maronpot, R., 2009. Furan-induced dose–response relationships for liver cytotoxicity, cell proliferation, and tumorigenicity (furan-induced liver tumorigenicity). Experimental and Toxicologic Pathology 61, 101-111.

Murakami, S., Motohashi, H., 2015. Roles of Nrf2 in cell proliferation and differentiation. Free Radic. Biol. Med. 88, 168-178.

Poungpairoj, P., Whongsiri, P., Suwannasin, S., Khlaiphuengsin, A., Tangkijvanich, P., Boonla, C., 2015. Increased Oxidative Stress and RUNX3 Hypermethylation in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma (HCC) and Induction of RUNX3 Hypermethylation by Reactive Oxygen Species in HCC Cells. Asian Pac. J. Cancer. Prev. 16, 5343-5348.

Schulze, K., Imbeaud, S., Letouze, E., Alexandrov, L.B., Calderaro, J., Rebouissou, S., Couchy, G., Meiller, C., Shinde, J., Soysouvanh, F., Calatayud, A.L., Pinyol, R., Pelletier, L., Balabaud, C., Laurent, A., Blanc, J.F., Mazzaferro, V., Calvo, F., Villanueva, A., Nault, J.C., Bioulac-Sage, P., Stratton, M.R., Llovet, J.M., Zucman-Rossi, J., 2015. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet. 47, 505-511.

Takahashi, S., Hirose, M., Tamano, S., Ozaki, M., Orita, S., Ito, T., Takeuchi, M., Ochi, H., Fukada, S., Kasai, H., Shirai, T., 1998. Immunohistochemical detection of 8-hydroxy-2'-deoxyguanosine in paraffin-embedded sections of rat liver after carbon tetrachloride treatment. Toxicol. Pathol. 26, 247-252.

Totoki, Y., Tatsuno, K., Covington, K.R., Ueda, H., Creighton, C.J., Kato, M., Tsuji, S., Donehower, L.A., Slagle, B.L., Nakamura, H., Yamamoto, S., Shinbrot, E., Hama, N., Lehmkuhl, M., Hosoda, F., Arai, Y., Walker, K., Dahdouli, M., Gotoh, K., Nagae, G., Gingras, M.C., Muzny, D.M., Ojima, H., Shimada, K., Midorikawa, Y., Goss, J.A., Cotton, R., Hayashi, A., Shibahara, J., Ishikawa, S., Guiteau, J., Tanaka, M., Urushidate, T., Ohashi, S., Okada, N., Doddapaneni, H., Wang, M., Zhu, Y., Dinh, H., Okusaka, T., Kokudo, N., Kosuge, T., Takayama, T., Fukayama, M., Gibbs, R.A., Wheeler, D.A., Aburatani, H., Shibata, T., 2014. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat. Genet. 46, 1267-1273.

Wacker, M., Wanek, P., Eder, E., 2001. Detection of 1,N2-propanodeoxyguanosine adducts of trans-4-hydroxy-2-nonenal after gavage of trans-4-hydroxy-2-nonenal or induction of lipid peroxidation with carbon tetrachloride in F344 rats. Chem. Biol. Interact. 137, 269-283.

Wang, E., Chen, F., Hu, X., Yuan, Y., 2014. Protective effects of apigenin against furan-induced toxicity in mice. Food Funct. 5, 1804-1812.

Wang, Y., Millonig, G., Nair, J., Patsenker, E., Stickel, F., Mueller, S., Bartsch, H., Seitz, H.K., 2009. Ethanol-induced cytochrome P4502E1 causes carcinogenic etheno-DNA lesions in alcoholic liver disease. Hepatology 50, 453-461.

Winczura, A., Zdzalik, D., Tudek, B., 2012. Damage of DNA and proteins by major lipid peroxidation products in genome stability. Free Radic. Res. 46, 442-459.

Xiang, M., Namani, A., Wu, S., Wang, X., 2014. Nrf2: Bane or blessing in cancer? J. Cancer Res. Clin. Oncol. 140, 1251-1259.

Zhang, T.T., Zhao, G., Li, X., Xie, F.W., Liu, H.M., Xie, J.P., 2015. Genotoxic and oxidative stress effects of 2-amino-9H-pyrido[2,3-b]indole in human hepatoma G2 (HepG2) and human lung alveolar epithelial (A549) cells. Toxicol. Mech. Methods 25, 212-222.